KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Income towards Parent Company: 2010-2024

Historic Income towards Parent Company for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $73.9 million.

  • Supernus Pharmaceuticals' Income towards Parent Company fell 217.20% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 131.95%. This contributed to the annual value of $73.9 million for FY2024, which is 5512.84% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Income towards Parent Company is $73.9 million, which was up 5,512.84% from $1.3 million recorded in FY2023.
  • Supernus Pharmaceuticals' Income towards Parent Company's 5-year high stood at $127.0 million during FY2020, with a 5-year trough of $1.3 million in FY2023.
  • In the last 3 years, Supernus Pharmaceuticals' Income towards Parent Company had a median value of $60.7 million in 2022 and averaged $45.3 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Income towards Parent Company plummeted by 97.83% in 2023, and later surged by 5,512.84% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Income towards Parent Company (Yearly) stood at $127.0 million in 2020, then crashed by 57.92% to $53.4 million in 2021, then grew by 13.64% to $60.7 million in 2022, then tumbled by 97.83% to $1.3 million in 2023, then surged by 5,512.84% to $73.9 million in 2024.